Skip to main content
Clinical Trials/NL-OMON31229
NL-OMON31229
Completed
Not Applicable

Activating the frontal brain in schizophrenia: comparison of aripiprazole versus resperidone using functional magnetic resonance imaging - MRI study on the effect of Abilify versus Risperdal

niversitair Medisch Centrum Groningen0 sites44 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
chronic psychosis
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
44
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • People diagnozed for schizophrenia according to DSM\-IV. They should not repsond to first choiche treatment or suffer from serious side effects.
  • Besides, healthy control without high education level.

Exclusion Criteria

  • Subjects with a psychiatric or neurologic disease other than schizophrenia, for which they have been treated. Presence of MRI incompatible implants. For safety reasons female participants who may be pregnant will be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials